Loading patent…
AssigneeSupratek Pharma Inc.
InventorsLioudmila Tchistiakova, Shengmin Li, Grzegorz Pietrzynski, Valery Alakhov
Estimating the term…
The present invention relates to compositions comprised of a peptide ligand or derivatives thereof that are capable of specific binding to the high affinity receptor-1 of vascular endothelial growth factor (VEGF) and structure similar receptors. The invention further provides a peptide ligand or derivatives thereof that are capable of inhibiting angiogenesis induced by VEGF. The present invention also provides a method for treatment or diagnosis of disease associated with angiogenesis in a patient in need of therapy comprising administering to the patient an effective amount of the pharmaceutical composition of the present invention and a pharmaceutical acceptable carrier.
A pharmaceutical composition comprising at least one peptide or derivative thereof, wherein said polypeptide or derivative thereof is capable of specific binding with the high affinity VEGF receptor-1 or a derivative of the VEGF receptor-1 and structural similar receptors.
An isolated nucleic acid encoding the polypeptide or derivatives thereof comprising amino acid sequences of SEQ. ID. NOs.:
A composition comprising a nucleic acid molecule and carrier, wherein the nucleic acid molecule encodes a polypeptide encoding the amino acid sequence of SEQ. ID. NOs.:
Dependencies are inferred from the claim text.